company background image
BCAB logo

BioAtla NasdaqGM:BCAB Stock Report

Last Price

US$3.44

Market Cap

US$166.4m

7D

42.7%

1Y

39.8%

Updated

28 Mar, 2024

Data

Company Financials +

BCAB Stock Overview

BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer.

BCAB fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

BioAtla, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for BioAtla
Historical stock prices
Current Share PriceUS$3.44
52 Week HighUS$4.07
52 Week LowUS$1.24
Beta1
1 Month Change21.13%
3 Month Change39.84%
1 Year Change39.84%
3 Year Change-93.27%
5 Year Changen/a
Change since IPO-88.91%

Recent News & Updates

Will BioAtla (NASDAQ:BCAB) Spend Its Cash Wisely?

Mar 14
Will BioAtla (NASDAQ:BCAB) Spend Its Cash Wisely?

Recent updates

Will BioAtla (NASDAQ:BCAB) Spend Its Cash Wisely?

Mar 14
Will BioAtla (NASDAQ:BCAB) Spend Its Cash Wisely?

Is BioAtla (NASDAQ:BCAB) In A Good Position To Deliver On Growth Plans?

Nov 05
Is BioAtla (NASDAQ:BCAB) In A Good Position To Deliver On Growth Plans?

We Think BioAtla (NASDAQ:BCAB) Needs To Drive Business Growth Carefully

Jun 27
We Think BioAtla (NASDAQ:BCAB) Needs To Drive Business Growth Carefully

Will BioAtla (NASDAQ:BCAB) Spend Its Cash Wisely?

Mar 24
Will BioAtla (NASDAQ:BCAB) Spend Its Cash Wisely?

BioAtla (NASDAQ:BCAB) Is In A Good Position To Deliver On Growth Plans

Sep 27
BioAtla (NASDAQ:BCAB) Is In A Good Position To Deliver On Growth Plans

BioAtla: Back From The Dead

Sep 23

BioAtla: Promising Signal In NSCLC, But Concerns Remain

Aug 23

BioAtla reports Q2 results

Aug 09

We're Keeping An Eye On BioAtla's (NASDAQ:BCAB) Cash Burn Rate

May 11
We're Keeping An Eye On BioAtla's (NASDAQ:BCAB) Cash Burn Rate

Companies Like BioAtla (NASDAQ:BCAB) Are In A Position To Invest In Growth

Jan 06
Companies Like BioAtla (NASDAQ:BCAB) Are In A Position To Invest In Growth

BioAtla (NASDAQ:BCAB) Is In A Good Position To Deliver On Growth Plans

Jul 24
BioAtla (NASDAQ:BCAB) Is In A Good Position To Deliver On Growth Plans

Are Insiders Buying BioAtla, Inc. (NASDAQ:BCAB) Stock?

Mar 16
Are Insiders Buying BioAtla, Inc. (NASDAQ:BCAB) Stock?

Shareholder Returns

BCABUS BiotechsUS Market
7D42.7%0.9%0.4%
1Y39.8%10.3%28.8%

Return vs Industry: BCAB exceeded the US Biotechs industry which returned 10.3% over the past year.

Return vs Market: BCAB exceeded the US Market which returned 28.8% over the past year.

Price Volatility

Is BCAB's price volatile compared to industry and market?
BCAB volatility
BCAB Average Weekly Movement16.8%
Biotechs Industry Average Movement11.6%
Market Average Movement6.0%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: BCAB's share price has been volatile over the past 3 months.

Volatility Over Time: BCAB's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
200765Jay Shorthttps://www.bioatla.com

BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company’s lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer that is in Phase II clinical trial. Its products under clinical development include BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and head and neck cancer which is in Phase II clinical trial; BA3071, a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer that is in Phase II clinical trial; and BA3182, a CAB bispecific candidate that is in Phase I clinical trial for the treatment of adenocarcinomas.

BioAtla, Inc. Fundamentals Summary

How do BioAtla's earnings and revenue compare to its market cap?
BCAB fundamental statistics
Market capUS$166.41m
Earnings (TTM)-US$123.46m
Revenue (TTM)n/a

0.0x

P/S Ratio

-1.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BCAB income statement (TTM)
RevenueUS$0
Cost of RevenueUS$103.73m
Gross Profit-US$103.73m
Other ExpensesUS$19.73m
Earnings-US$123.46m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-2.57
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did BCAB perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.